{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"304","value":"43"},{"groupId":"OG001","lowerLimit":"9","upperLimit":"890","value":"82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Time to progression was defined as the interval between the first date of treatment and the first notation of disease progression.","dispersionType":"Full Range","groups":[{"description":"CTCL patients will receive 1000 mg/m2 of PXD101 IV\n\nbelinostat: 1000 mg/m2 for 5 days every 21 days; IV","id":"OG000","title":"Arm A (CTCL, ITT Population)"},{"description":"PTCL patients will receive 1000 mg/m2 of PXD101 IV\n\nbelinostat: 1000 mg/m2 for 5 days every 21 days; IV","id":"OG001","title":"Arm B (PTCL, ITT Population)"}],"paramType":"MEDIAN","populationDescription":"Time to Progression (ITT population) was estimated using the Kaplan-Meier method for CTCL and PTCL arms. As progression was not observed in six patients in Arm A and 10 patients in Arm B, a total of 37 patients progressed, and the the median time to progression and the full range (days) are presented.","reportingStatus":"POSTED","timeFrame":"throughout the study, or for a maximum of 2 years","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"Days"}